These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 25739820)

  • 41. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
    Cusi K
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):141-9. PubMed ID: 19262374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.
    Parekh S; Anania FA
    Gastroenterology; 2007 May; 132(6):2191-207. PubMed ID: 17498512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications.
    Andronescu CI; Purcarea MR; Babes PA
    J Med Life; 2018; 11(1):20-23. PubMed ID: 29696060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The molecular mechanisms between metabolic syndrome and breast cancer.
    Chen Y; Wen YY; Li ZR; Luo DL; Zhang XH
    Biochem Biophys Res Commun; 2016 Mar; 471(4):391-5. PubMed ID: 26891869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?
    Tarantino G; Citro V; Finelli C
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):359-68. PubMed ID: 26405708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to 'Effect of metabolic components on incident type 2 diabetes mellitus in nonalcoholic fatty liver disease subjects'.
    Fukuda T; Hamaguchi M; Fukui M
    Liver Int; 2016 Mar; 36(3):462. PubMed ID: 26442842
    [No Abstract]   [Full Text] [Related]  

  • 48. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease.
    Catanzaro R; Cuffari B; Italia A; Marotta F
    World J Gastroenterol; 2016 Sep; 22(34):7660-75. PubMed ID: 27678349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Metabolic syndrome and nonalcoholic fatty liver diseases in children].
    Zakharova IN; Zvenigorodskaia LA; Iablochkova SV
    Eksp Klin Gastroenterol; 2011; (11):44-8. PubMed ID: 22629718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Framingham Heart Study--67 years of discovery in metabolic disease.
    Long MT; Fox CS
    Nat Rev Endocrinol; 2016 Mar; 12(3):177-83. PubMed ID: 26775764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quality of life in patients with nonalcoholic fatty liver disease in combination with essential hypertension considering taste sensitivity to sodium chloride.
    Mashura HY; Hanych TM; Rishko AA
    Wiad Lek; 2016; 69(2 Pt 2):204-7. PubMed ID: 27487534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of nonalcoholic fatty liver: present and emerging therapies.
    Angulo P; Lindor KD
    Semin Liver Dis; 2001; 21(1):81-8. PubMed ID: 11296699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707).
    Kim MK
    Diabetes Metab J; 2021 Nov; 45(6):968-969. PubMed ID: 34847645
    [No Abstract]   [Full Text] [Related]  

  • 54. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707).
    Han E; Kim HS
    Diabetes Metab J; 2021 Nov; 45(6):972-973. PubMed ID: 34847647
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinically Relevant Mechanisms of Lipid Synthesis, Transport, and Storage.
    Kalish BT; Fell GL; Nandivada P; Puder M
    JPEN J Parenter Enteral Nutr; 2015 Sep; 39(1 Suppl):8S-17S. PubMed ID: 26187937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical importance of the nonalcoholic fatty liver disease: a review.
    Chumak AA; Ovsyannikova LM; Sarkisova EA; Gasanova EV
    Probl Radiac Med Radiobiol; 2013; (18):277-88. PubMed ID: 25191732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treating the patient with nonalcoholic fatty liver disease.
    Chaney A
    Nurse Pract; 2015 Nov; 40(11):36-42; quiz 42-3. PubMed ID: 26474202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The association between nonalcoholic fatty liver disease and metabolic comorbidities.
    Zhao Q; Tang X; Wu J
    Hepatology; 2018 Jun; 67(6):2474. PubMed ID: 29251795
    [No Abstract]   [Full Text] [Related]  

  • 59. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.
    Polyzos SA; Kang ES; Tsochatzis EA; Kechagias S; Ekstedt M; Xanthakos S; Lonardo A; Mantovani A; Tilg H; Côté I; Grefhorst A; Greene MW; Araujo-Vilar D; Alisi A; Casanueva F; Mantzoros CS
    Metabolism; 2020 Dec; 113():154413. PubMed ID: 33164861
    [No Abstract]   [Full Text] [Related]  

  • 60. An AGTR1 Variant Worsens Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome.
    de Gracia Hahn D; Duret A; Mann JP
    Am J Gastroenterol; 2019 Apr; 114(4):556-559. PubMed ID: 30951517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.